

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful

FULL SEARCH INITIATED 18:01:46 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1419 TO ITERATE

100.0% PROCESSED 1419 ITERATIONS

6 ANSWERS

SEARCH TIME: 00.00.01

L2 6 SEA SSS FUL L1

=> d 1-6

L2 ANSWER 1 OF 6 REGISTRY COPYRIGHT 2007 ACS on STN

RN 685564-38-9 REGISTRY

ED Entered STN: 25 May 2004


CN Carbonic acid, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6-(acetyloxy)-12-(benzoyloxy)-3,4,4a,5,6,9,10,11,12,12a-decahydro-4,9,11,?,?-pentahydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-12b(2aH)-yl methyl ester (9CI) (CA INDEX NAME)

MF C31 H38 O14

CI IDS

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER




2 (D1-OH)

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 2 OF 6 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 685564-30-1 REGISTRY
 ED Entered STN: 25 May 2004
 CN Carbonic acid, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6-(acetyloxy)-12-(benzoyloxy)-3,4,4a,5,6,9,10,11,12,12a-decahydro-4,9,11,?-tetrahydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-12b(2aH)-yl methyl ester (9CI) (CA INDEX NAME)
 MF C31 H38 O13
 CI IDS
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER




D1-OH

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 3 OF 6 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 685096-39-3 REGISTRY
 ED Entered STN: 24 May 2004
 CN Carbonic acid, (2aR,4R,4aS,6R,9S,11S,12S,12aR,12bS)-6-(acetyloxy)-12-(benzoyloxy)-3,4,4a,5,6,9,10,11,12,12a-decahydro-4,9,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-12b(2aH)-yl methyl ester (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C31 H38 O12
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 4 OF 6 REGISTRY COPYRIGHT 2007 ACS on STN
RN 685096-38-2 REGISTRY
ED Entered STN: 24 May 2004
CN Acetic acid, hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,9,11-trihydroxy-12b-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-6-yl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H38 O13
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 5 OF 6 REGISTRY COPYRIGHT 2007 ACS on STN
RN 685096-28-0 REGISTRY
ED Entered STN: 24 May 2004
CN Carbonic acid, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6-(acetyloxy)-12-(benzoyloxy)-3,4,4a,5,6,9,10,11,12,12a-decahydro-4,9,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-12b(2aH)-yl methyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H38 O12
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 6 OF 6 REGISTRY COPYRIGHT 2007 ACS on STN
RN 685096-27-9 REGISTRY
ED Entered STN: 24 May 2004
CN 7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete-8-carboxylic acid, 6-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,9,11-trihydroxy-12b-[(methoxycarbonyl)oxy]-4a,13,13-trimethyl-5-oxo-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H36 O14
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
184.25	212.41

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-0.78

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 18:02:10 ON 07 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 May 2007 VOL 146 ISS 20

FILE LAST UPDATED: 6 May 2007 (20070506/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 12

L3 1 L2

=> d fbib abs hitstr

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN


AN 2004:368898 CAPLUS
 DN 140:375336
 TI Characterization of taxane metabolites useful as tumor-growth inhibitors
 IN Comezoglu, S. Nilgun
 PA Bristol-Myers Squibb Company, USA
 SO PCT Int. Appl., 113 pp.
 CODEN: PIXXD2

DT Patent
 LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004037211	A2	20040506	WO 2003-US34083	20031024
	WO 2004037211	A3	20040916		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2003285005	A1	20040513	US 2002-421405P	P 20021025
				AU 2003-285005	20031024
				US 2002-421405P	P 20021025
				WO 2003-US34083	W 20031024
	EP 1556030	A2	20050727	EP 2003-779320	20031024
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
				US 2002-421405P	P 20021025
				WO 2003-US34083	W 20031024

GI



I




II

AB This invention relates to compds. that are metabolites of 3'-tert-butyl-3'-N-(tert-butyloxycarbonyl)-4-deacetyl-3'-dephenyl-3'-N-debenzoyl-4-O-(methoxycarbonyl)paclitaxel. The compds., e.g. I [R1 = SG,

OMe, OH, H, ; R2 = H, OH, OMe; R3 = Me, CO2H; R4 = H, OH, (OH)2; SG = SCH2CH(CONHCH2CO2H)NHCOCH2CH2CH(NH2)CO2H] and II [R1 = Me, CO2H; R2 = H, OH; R3 = COMe, H, COCH2OH; R4 = H, CO2Me], or a pharmaceutically acceptable salt, solvate or prodrug, are useful as therapeutic agents, especially as tumor-growth inhibitors. Thus, 14C-, 13C- and unlabeled 3'-tert-butyl-3'-N-(tert-butyloxycarbonyl)-4-deacetyl-3'-dephenyl-3'-N-debenzoyl-4-O-(methoxycarbonyl)paclitaxel were incubated with liver microsomes from various mammals and the metabolites were isolated and characterized.


IT 685096-27-9P 685096-28-0P 685096-38-2P
685096-39-3P 685564-30-1DP, baccatin-ring hydroxyl regioisomers or epimer
RL: BMF (Bioindustrial manufacture); BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(characterization of taxane metabolites useful as tumor-growth inhibitors)
RN 685096-27-9 CAPLUS
CN 7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete-8-carboxylic acid, 6-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,9,11-trihydroxy-12b-[(methoxycarbonyl)oxy]-4a,13,13-trimethyl-5-oxo-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 685096-28-0 CAPLUS
CN Carbonic acid, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6-(acetyloxy)-12-(benzoyloxy)-3,4,4a,5,6,9,10,11,12,12a-decahydro-4,9,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-12b(2aH)-yl methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685096-38-2 CAPLUS

CN Acetic acid, hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,9,11-trihydroxy-12b-[(methoxycarbonyl)oxy]-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-6-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 685096-39-3 CAPLUS


CN Carbonic acid, (2aR,4R,4aS,6R,9S,11S,12S,12aR,12bS)-6-(acetyloxy)-12-(benzoyloxy)-3,4,4a,5,6,9,10,11,12,12a-decahydro-4,9,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-12b(2aH)-yl methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 685564-30-1 CAPLUS

CN Carbonic acid, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6-(acetyloxy)-12-(benzoyloxy)-3,4,4a,5,6,9,10,11,12,12a-decahydro-4,9,11,?-tetrahydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-12b(2aH)-yl methyl ester (9CI) (CA INDEX NAME)



D1-OH


IT 685564-38-9P

RL: BMF (Bioindustrial manufacture); BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)



(incubation of, with mammal liver microsomes; characterization of taxane metabolites useful as tumor-growth inhibitors)

RN 685564-38-9 CAPLUS

CN Carbonic acid, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6-(acetyloxy)-12-(benzoyloxy)-3,4,4a,5,6,9,10,11,12,12a-decahydro-4,9,11,?,?-pentahydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-12b(2aH)-yl methyl ester (9CI) (CA INDEX NAME)



2 (D1-OH)



chain nodes :

12 13 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 14 15 16 17 18 19

chain bonds :

2-24 3-23 6-13 7-25 7-26 8-12 9-21 11-22 13-28 14-20 16-27 24-35 27-31 28-29 28-30
31-32 31-33 33-34 35-36 35-37

ring bonds :

1-2 1-7 1-9 2-3 3-4 4-5 4-14 5-6 5-16 6-8 7-8 8-10 9-11 10-11 14-15 15-17 16-17 16-18
17-19 18-19

exact/norm bonds :

1-2 1-7 1-9 2-3 2-24 3-4 3-23 4-5 4-14 5-6 5-16 6-8 6-13 7-8 8-10 8-12 9-11 10-11
11-22 13-28 14-15 14-20 15-17 16-17 16-18 16-27 17-19 18-19 24-35 27-31 28-29 31-32
31-33 33-34 35-37

exact bonds :

7-25 7-26 9-21 28-30 35-36

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:CLASS
13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:Atom 20:CLASS 21:CLASS 22:CLASS
23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS
33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS

0/532 533

EAST - [space that works.wsp:1]

Search History

Grid Prefs... Font... Print Font: "Tahoma", Size: 10

Ref # Δ	Hits	Search Query	DBs
L1	1133	((549/510) or (514/449)).CCLS.	USPAT
L2	364	l1 and paclitaxel	USPAT
L3	46	l2 and metabolite	USPAT
L4	46	l2 and metabolite	US-PGPUB; USPAT

Row Separation for Printout

☒ None
☐ Shading
☐ Lines

Include active and saved searches from the following folders in Search History

☒ Active
☐ Saved
☐ Favorites
☐ Failed
☐ Trash

Print Selection... Select All
Print All... Clear All
Save Selection... Close
Save All... Help